These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28006819)

  • 1. Better resource utilisation and quality of care for ovarian cancer patients using internet-based pathology review.
    Kommoss S; Kommoss F; Diebold J; Lax S; Schmidt D; Staebler A; du Bois A; Pfisterer J
    Br J Cancer; 2017 Jan; 116(3):287-292. PubMed ID: 28006819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specialized pathology review in patients with ovarian cancer: results from a prospective study.
    Kommoss S; Pfisterer J; Reuss A; Diebold J; Hauptmann S; Schmidt C; du Bois A; Schmidt D; Kommoss F
    Int J Gynecol Cancer; 2013 Oct; 23(8):1376-82. PubMed ID: 24257551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Specialized histopathological second opinion of advanced ovarian cancer. Experiences with collectives from prospective randomized phase III studies].
    Kommoss S; Pfisterer J; du Bois A; Schmidt D; Kommoss F
    Pathologe; 2014 Jul; 35(4):355-60. PubMed ID: 24992975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. iPathology cockpit diagnostic station: validation according to College of American Pathologists Pathology and Laboratory Quality Center recommendation at the Hospital Trust and University of Verona.
    Brunelli M; Beccari S; Colombari R; Gobbo S; Giobelli L; Pellegrini A; Chilosi M; Lunardi M; Martignoni G; Scarpa A; Eccher A
    Diagn Pathol; 2014; 9 Suppl 1(Suppl 1):S12. PubMed ID: 25565219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review.
    Kommoss S; Gilks CB; Kommoss F; Chow C; Hilpert F; du Bois A; Köbel M; Huntsman DG; Anglesio M; Kalloger SE; Pfisterer J
    Histopathology; 2013 Nov; 63(5):704-12. PubMed ID: 24033430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of quality of gynaecological ultrasonography on management of patients with suspected ovarian cancer: a randomised controlled trial.
    Yazbek J; Raju SK; Ben-Nagi J; Holland TK; Hillaby K; Jurkovic D
    Lancet Oncol; 2008 Feb; 9(2):124-31. PubMed ID: 18207461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Assessment of Synoptic Pathology Reporting for Ovarian Cancer.
    Słodkowska J; Cierniak S; Patera J; Kopik J; Baranowski W; Markiewicz T; Murawski P; Buda I; Kozłowski W
    Pathobiology; 2016; 83(2-3):70-8. PubMed ID: 27100104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of ovarian cancer histopathology by registry pathologists and referral pathologists: a study by the Gilda Radner Familial Ovarian Cancer Registry.
    Piver MS; Tsukada Y; Werness BA; DiCioccio RA; Whittemore AS; Ponder BA
    Gynecol Oncol; 2000 Aug; 78(2):166-70. PubMed ID: 10926797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central pathology review in multicenter trials and studies: lessons from the nephroblastoma trials.
    Vujanić GM; Sandstedt B; Kelsey A; Sebire NJ
    Cancer; 2009 May; 115(9):1977-83. PubMed ID: 19241454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The accurate staging of ovarian cancer using 3T magnetic resonance imaging--a realistic option.
    Booth SJ; Turnbull LW; Poole DR; Richmond I
    BJOG; 2008 Jun; 115(7):894-901. PubMed ID: 18485169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the problem of inadequately staging early ovarian cancer.
    Timmers PJ; Zwinderman AH; Coens C; Vergote I; Trimbos JB
    Eur J Cancer; 2010 Mar; 46(5):880-4. PubMed ID: 20074933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
    Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
    Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current status of surgical staging of ovarian serous borderline tumors.
    Lin PS; Gershenson DM; Bevers MW; Lucas KR; Burke TW; Silva EG
    Cancer; 1999 Feb; 85(4):905-11. PubMed ID: 10091769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
    Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of rare ovarian cancers: the experience of the French website "Observatory for rare malignant tumours of the ovaries" by the GINECO group: interim analysis of the first 100 patients.
    Ray-Coquard I; Weber B; Lotz JP; Tournigand C; Provencal J; Mayeur D; Treilleux I; Paraiso D; Duvillard P; Pujade-Lauraine E;
    Gynecol Oncol; 2010 Oct; 119(1):53-9. PubMed ID: 20580063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers in France].
    Ray-Coquard I; Pautier P; Pujade-Lauraine E; Méeus P; Morice P; Treilleux I; Duvillard P; Alexandre J; Lhommé C; Selle F; Guastalla J
    Bull Cancer; 2010 Jan; 97(1):123-35. PubMed ID: 20007069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From telepathology to virtual pathology institution: the new world of digital pathology.
    Kayser K; Kayser G; Radziszowski D; Oehmann A
    Rom J Morphol Embryol; 1999-2004; 45():3-9. PubMed ID: 15847374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer.
    Weinberg LE; Rodriguez G; Hurteau JA
    J Surg Oncol; 2010 Mar; 101(4):334-43. PubMed ID: 20187069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.